Shenzhen Drawray Biotech Co., Ltd. (hereinafter referred to as “Drawray”) was established in May 2019. The company is a wholly-owned subsidiary of YHLO ( https://en.szyhlo.com/ ) and it mainly engages in the R&D, production, sales and service of products in the field of diagnostics (IVD).

Drawray strictly follow the company's quality policy and has passed ISO 13485 and ISO 9001 system certifications. Draway has five in-vitro diagnostic technology platforms including CLIA, FIA, Microfluidics, Rapid Test and PCR. Its products cover cardiac markers, thyroid function, endocrine hormones, autoimmunity, respiratory viruses, reproductive health, bone metabolism, inflammation and infection, liver disease monitoring, allergen detection and other diagnosis fields. With continuous involvement in research and development every year, we have achieved over 90 CE and more than 40 patents.

Drawray will always uphold the mission of "Technological innovation brings life care all around", with the vision of "becoming a leader in the field of rapid diagnosis", and strive to help people all over the world improve medical conditions and reduce medical costs. With the goal mentioned above, we will accurately assess future needs, create new value, and make unremitting efforts for human health and technological innovation.